Glenmark Pharma: Progress in clinical trial

The Glenmark scrip will remain active as it has completed the phase I enabling preclinical development program for GBR 830 and filed a phase I clinical trial application with the Netherlands authorities. GBR 830 is the first OX40 antagonistic antibody devoid of agonistic properties to enter clinical studies. GBR 830 targets auto-reactive T cells that drive the pathology in most autoimmune diseases, including, but not limited to, illnesses such as rheumatoid arthritis and lupus.